That is a cracking deal for a clinical stage bio. Interesting that they have a p1 and p3 drug in the rare disease space with BTD and a massive MC compared to us. They do have extremely good results but $8.7 bill t/o is mind boggling !
It does make you wonder whether we will see a big upfront with a multi bill back ended deal in a structured m/a type setup. These other deals in the high billions do make you wonder just how big the back ended milestones could really be
Also highlights how big the difference is in biotech land valuation of the Nasdaq and ASX
Add to My Watchlist
What is My Watchlist?
